-The Times of India So much has already been written on the food security Bill that there would seem to be no justification for another column on it. Yet, a recent look at some consumption data has convinced me otherwise. How the food security Bill impacts people's lives ultimately depends on the effect it will have on the consumption basket of the beneficiaries. If you believe in serious analysis over flag waving,...

-The Business Standard Angelina Jolie has inadvertently highlighted a key question about patenting Angelina Jolies recent double mastectomy was obviously a very radical decision. It is unusual for a healthy person to opt for pre-emptive surgery to avert the probability, however high it may be, of getting cancer. The tests Jolie relied on are also at the heart of a legal battle, which could affect US biotech patenting norms. Since the US...

-The Times of India NEW DELHI: If the dictum 'you can't manage what you can't measure' is true, then the government has an unsure grip over at least half the 13 flagship schemes worth nearly Rs 2 lakh crore annually, almost 80% of the total spend on central schemes. The government is unable to efficiently collate information to assess whether some of the 13 key flagship schemes are producing the results for...

Argumentative Indians are at it again! After sparring over the poverty line and the actual number of poor, India's renowned economists have fired up a fresh debate over the extent of malnutrition. In the earlier debate, the Planning Commission ‘reduced' poverty on paper disregarding NSSO and official committees, including the NCEUS, which determined that 77% Indians survived on less than Rs 20 a day. Columbia university economist Arvind Panagariya has...

-The Hindu   Ranbaxy's fraudulent practices may have jeopardised millions of lives in India, Africa and the U.S. Exactly two weeks ago, the pharmaceuticals industry was rocked by revelations that one of the world's largest generic drug manufacturers, Ranbaxy Laboratories, pleaded guilty to seven federal criminal charges stemming from its fraudulent production practices dating back to 2008, and agreed to pay U.S. regulators $500 million in fines. Much has since been said about Ranbaxy's...